top of page

Jaya Mini Gill, M.D., MHA, BSN, RN

Executive Director

  • LinkedIn
Mini Gill
Mini Gill Bio


Jaya Mini Gill is a highly accomplished professional in the field of clinical research. She has provided administrative leadership and operational management of clinical research, developed trial protocols, and fostered relationships with research sponsors, partners, and the community. 
Prior to her current role, Jaya has held several key positions in clinical research at Pacific Neuroscience Institute Foundation and John Wayne Cancer Institute. In these roles, she managed research activities, supervised clinical teams, supported financial performance of clinical trials, and ensured regulatory compliance.
Jaya's career in clinical research was preceded by her experience as a Critical Care Registered Nurse at Providence Saint John’s Health Center, where she provided high-intensity care to patients with acute health problems. She also has a background in biomechanics research, having worked as a Research Associate and Assistant at UCLA Department of Orthopaedic Surgery’s Biomechanics Research Division.
Jaya holds a Doctor of Medicine degree from American University of the Caribbean School of Medicine, a Master’s in Health Administration from West Coast University, a Bachelor’s in Nursing from California State University Northridge, and a Bachelor’s in Biology from University of California, Los Angeles. She is a member of several professional organizations, holds various licenses and certifications, and has contributed to numerous publications, presentations, and clinical trials.
Her extensive experience, combined with her educational background and commitment to advancing clinical research, make Jaya Mini Gill a distinguished professional in her field.

Most Recent Publications

1. Liu A, Alalami H, Fan X, Patil C, Gill JM, Kesari S, Hu J. Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS. CNS Oncol. 2023 Sep 1;12(3): CNS 100. Epub 2023/07/12. doi:10.2217/cns-2022-0021. PMID 37435740.

2. Kesari S, Wang F, Juarez T, Ashili S, Patro CPK, Carrillo J, Nguyen M, Truong J, Levy J, Sommer J, Freed DM, Xiu J, Takasumi Y, Bouffet E, Gill JM. Activity of pemetrexed in pre-clinical chordoma models and humans. Sci Rep. 2023 May 5;13(1):7317. Epub 2023/05/06. doi:10.1038/s41598-023-34404-4. PMID 37147496.

3. Hammond TC, Lee RC, Oronsky B, Reid TR, Caroen S, Juarez TM, Gill J, Heng A, Kesari S. Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001. Int Med Case Rep J. 2022;15:735-738. Epub 2022/12/23. doi:10.2147/IMCRJ.S389690. PMID 36545548.

4. Meysami S, Raji CA, Glatt RM, Popa ES, Ganapathi AS, Bookheimer T, Slyapich CB, Pierce KP, Richards CJ, Lampa MG, Gill JM, Rapozo MK, Hodes JF, Tongson YM, Wong CL, Kim M, Porter VR, Kaiser SA, Panos SE, Dye RV, Miller KJ, Bookheimer SY, Martin NA, Kesari S, Kelly DF, Bramen JE, Siddarth P, Merrill DA. Handgrip Strength Is Related to Hippocampal and Lobar Brain Volumes in a Cohort of Cognitively Impaired Older Adults with Confirmed Amyloid Burden. J Alzheimers Dis. 2022 Dec 14. Epub 2022/12/20. doi:10.3233/JAD-220886. PMID 36530088.

5. Perez JA, Lopez JJ, Torres Badillo CC, Gill J, Kesari S, Novak P, Temnikov M, Byshovets R, Bychkov O. Correction: Phase 1 First-in-Human Dose Escalation and Dose Expansion Study of KLS-1 (64Zinc Aspartate) in Patients With Cancer and Neurodegenerative Diseases. Cureus. 2022 Oct;14(10):c78. Epub 2022/11/19. doi:10.7759/cureus.c78. PMID 36397903.

6. Ganapathi AS, Glatt RM, Bookheimer TH, Popa ES, Ingemanson ML, Richards CJ, Hodes JF, Pierce KP, Slyapich CB, Iqbal F, Mattinson J, Lampa MG, Gill JM, Tongson YM, Wong CL, Kim M, Porter VR, Kesari S, Meysami S, Miller KJ, Bramen JE, Merrill DA, Siddarth P. Differentiation of Subjective Cognitive Decline, Mild Cognitive Impairment, and Dementia Using qEEG/ERP-Based Cognitive Testing and Volumetric MRI in an Outpatient Specialty Memory Clinic. J Alzheimers Dis. 2022;90(4):1761-1769. Epub 2022/11/15. doi:10.3233/JAD-220616. PMID 36373320.

7. Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic JP, Flores JP, Fonkem E, McClay E, Nabors LB, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager System in patients with recurrent glioblastoma. CNS Oncol. 2023 Sep 1;12(3):CNS102. Epub 2023/07/18. doi:10.2217/cns-2022-0016. PMID 37462385

8. Weidhaas, J., Marco, N., Scheffler, A.W., Kalbasi, A., Wilenius, K., Rietdorf, E., Gill, J., Heilig, M., Desler, C., Chin, R.K., Kaprealian, T., McCloskey, S., Raldow, A., Raja, N.P., Kesari, S., Carrillo, J., Drakaki, A., Scholz, M., Telesca, D. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy. Journal Immunotherapy Cancer. 2022 Feb; 10(2). 

9. Yalamanchi, A., Gill, J., Truong, J., Nguyen, M., Carrillo, J., Wagle, N., Sharma, A., Kesari, S. Molecularly targeted treatment of recurrent anaplastic astrocytoma – a case report. Annals of Clinical and Translational Neurology. 2021.

10. Yalamanchi, M., Sharma, A., Nguyen, M., Truong, J., Carrillo, J., Wagle, N., Gill, J. & Kesari, S. Successful and durable response of primary CNS T-cell lymphoma to upfront temozolomide monotherapy. Leukemia & Lymphoma. 2021.
bottom of page